All News

Expert shares notable findings presented at the 2025 IMS Annual Meeting.

Lawmakers weigh cost concerns, clinical outcomes, and regulatory barriers as access to these medications evolves.

Explore the impact of extrapyramidal symptoms on patients, including drug-induced parkinsonism and dystonia, and the importance of early detection and management.

Explore effective non-hormonal treatment options for menopause-related vasomotor symptoms, including hot flashes and night sweats, with insights from pharmacists.

A phase 2 trial suggests a stepwise regimen using liposomal irinotecan followed by oxaliplatin may improve progression-free survival over standard treatment.

The FDA updates sotatercept's label, enhancing treatment options for pulmonary arterial hypertension and reducing severe clinical events.

Pharmacy professionals should make informed decisions regarding their individual career paths.

Research highlights the link between earlier menopause, cardiac function, and brain health, emphasizing the need for sex-specific dementia risk strategies.

Research highlights the impact of provider type on menopause treatment, revealing a need for standardized education to improve care quality for women.

Elinzanetant, the first FDA-approved nonhormonal treatment for menopause-related hot flashes, offers women a new, effective relief option.

Revumenib was approved for adults and pediatric patients 1 year and older with relapsed or refractory acute myeloid leukemia.

Explore the promising data on elinzanetant for managing menopause-related vasomotor symptoms, highlighting its tolerability and minimal side effects.

A heightened ratio of non-high-density lipoprotein cholesterol (non-HDL-C) to HDL-C was associated with depression, with risk mediated by body mass index.

This quiz was created in collaboration with PTCE™.

The authors wrote that their findings show a necessary update following early data from the Women’s Health Initiative.

Influenza vaccination provided direct, non–infection-based benefits in older adults.

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

Samantha Picking, PharmD, highlights pharmacists’ leadership in immunization initiatives, public health collaborations, and the evolving role of community pharmacy in preventive care.

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma, enhancing treatment options and survival rates for patients with limited therapies.

If approved, SYD-101 would have been the first FDA-approved treatment for pediatric myopia, offering hope to millions of affected children in the US.

New research highlights the enhanced humoral response in lymphoma survivors receiving two doses of the PCV20 vaccine, emphasizing vaccination's critical role in infection prevention.

Megan Dulohery Scrodin, MD, highlights Mayo Clinic's innovative COPD care model, emphasizing multidisciplinary collaboration and AI tools for improved patient outcomes.

Initiatives aim to reduce residents' high rates of depression and increase self-care skills.

Experts discuss breakthroughs in respiratory virus vaccines.

Elinzanetant shows promise as a new treatment for menopause-related vasomotor symptoms, offering rapid relief and a favorable safety profile.

New clinical trial results suggest G-CSF as a promising alternative for managing hot flashes in menopausal women, without the risks of traditional therapies.